<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03228342</url>
  </required_header>
  <id_info>
    <org_study_id>IRE-2218-17/19-1</org_study_id>
    <nct_id>NCT03228342</nct_id>
  </id_info>
  <brief_title>Ultrasound Impact in Rheumatoid Arthritis Patient Reported Outcomes</brief_title>
  <acronym>ULTRAPRO</acronym>
  <official_title>The Impact of Musculoskeletal Ultrasound-added to Clinical Evaluations- on Patient Reported Outcomes: A Prospective Study of Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity (ULTRAPRO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clínica de Artritis Temprana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clínica de Artritis Temprana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the impact of MusculoSkeletal Ultrasound added to Rheumatoid Arthritis patients&#xD;
      classified in remission/low disease activity in terms of Patient Reported Outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (HAQ)</measure>
    <time_frame>From baseline at 6 months</time_frame>
    <description>Minimal Clinically Significant change in HAQ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (RADAI)</measure>
    <time_frame>from baseline at 6 months</time_frame>
    <description>Minimal Clinically Significant change in RADAI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (SF-36)</measure>
    <time_frame>from baseline at 6 months</time_frame>
    <description>Minimal Clinically Significant change in SF-36</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (VAS-Patient)</measure>
    <time_frame>from baseline at 6 months</time_frame>
    <description>Minimal Clinically Significant change in VAS-Patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasound findings in Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Describe ultrasound findings at the moment of inclusion in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse: Proportion of patients with relapse after the intervention in both groups</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>Describe the proportion of patients with relapse after the intervention in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (HAQ)</measure>
    <time_frame>from baseline at 12 months</time_frame>
    <description>Minimal Clinically Significant change in HAQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (RADAI)</measure>
    <time_frame>from baseline at 12 months</time_frame>
    <description>Minimal Clinically Significant change in RADAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (SF-36)</measure>
    <time_frame>from baseline at 12 months</time_frame>
    <description>Minimal Clinically Significant change in SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of the Patient Reported Outcome (VAS-Patient)</measure>
    <time_frame>from baseline at 12 months</time_frame>
    <description>Minimal Clinically Significant change in VAS-Patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Patient Reported Outcomes</condition>
  <condition>Musculoskeletal Ultrasound</condition>
  <arm_group>
    <arm_group_label>Ultrasound shared</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be assessed with ultrasound (GUS-7 score)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasound not shared</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be assessed with ultrasound (GUS-7 score)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MusculoSkeletal Ultrasound</intervention_name>
    <description>Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.&#xD;
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.</description>
    <arm_group_label>Ultrasound shared</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MusculoSkeletal Ultrasound</intervention_name>
    <description>Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.&#xD;
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.</description>
    <arm_group_label>Ultrasound not shared</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of RA made at the discretion of the attending experienced&#xD;
             rheumatologist.&#xD;
&#xD;
          -  Patients classified in remission/low disease activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;16 years old.&#xD;
&#xD;
          -  Patient with recent trauma in the evaluated joints.&#xD;
&#xD;
          -  Luxation in the MCP, PIP or MTP joints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Pascual, MD</last_name>
    <role>Study Director</role>
    <affiliation>INCMNSZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Plaza M, Nowakowska-Plaza A, Pracon G, Sudol-Szopinska I. Role of ultrasonography in the diagnosis of rheumatic diseases in light of ACR/EULAR guidelines. J Ultrason. 2016 Mar;16(64):55-64. doi: 10.15557/JoU.2016.0006. Epub 2016 Mar 29.</citation>
    <PMID>27104003</PMID>
  </reference>
  <reference>
    <citation>Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum. 2000 Dec;43(12):2762-70. doi: 10.1002/1529-0131(200012)43:123.0.CO;2-#.</citation>
    <PMID>11145034</PMID>
  </reference>
  <reference>
    <citation>Nakagomi D, Ikeda K, Okubo A, Iwamoto T, Sanayama Y, Takahashi K, Yamagata M, Takatori H, Suzuki K, Takabayashi K, Nakajima H. Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum. 2013 Apr;65(4):890-8. doi: 10.1002/art.37848.</citation>
    <PMID>23334942</PMID>
  </reference>
  <reference>
    <citation>Terslev L, von der Recke P, Torp-Pedersen S, Koenig MJ, Bliddal H. Diagnostic sensitivity and specificity of Doppler ultrasound in rheumatoid arthritis. J Rheumatol. 2008 Jan;35(1):49-53. Epub 2007 Dec 15.</citation>
    <PMID>18172922</PMID>
  </reference>
  <reference>
    <citation>Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011 Jan;70(1):172-5. doi: 10.1136/ard.2010.129924. Epub 2010 Nov 19.</citation>
    <PMID>21097799</PMID>
  </reference>
  <reference>
    <citation>Dale J, Purves D, McConnachie A, McInnes I, Porter D. Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken). 2014 Jan;66(1):19-26. doi: 10.1002/acr.22218.</citation>
    <PMID>24376248</PMID>
  </reference>
  <reference>
    <citation>Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12.</citation>
    <PMID>25969430</PMID>
  </reference>
  <reference>
    <citation>Galicia-Hernandez G, Parra-Salcedo F, Ugarte-Martinez P, Contreras-Yanez I, Ponce-de-Leon A, Pascual-Ramos V. Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):261-9. Epub 2016 Mar 3.</citation>
    <PMID>26939612</PMID>
  </reference>
  <reference>
    <citation>Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, Sattler H, Albrecht K, Kaufmann J, Becker K, Sorensen H, Meier L, Burmester GR, Schmidt WA. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum. 2009 Sep 15;61(9):1194-201. doi: 10.1002/art.24646.</citation>
    <PMID>19714611</PMID>
  </reference>
  <reference>
    <citation>Backhaus TM, Ohrndorf S, Kellner H, Strunk J, Hartung W, Sattler H, Iking-Konert C, Burmester GR, Schmidt WA, Backhaus M. The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Ann Rheum Dis. 2013 Jul;72(7):1163-9. doi: 10.1136/annrheumdis-2012-201397. Epub 2012 Sep 6.</citation>
    <PMID>22956596</PMID>
  </reference>
  <reference>
    <citation>Scire CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009 Sep;48(9):1092-7. doi: 10.1093/rheumatology/kep171. Epub 2009 Jun 26.</citation>
    <PMID>19561156</PMID>
  </reference>
  <reference>
    <citation>Saleem B, Brown AK, Quinn M, Karim Z, Hensor EM, Conaghan P, Peterfy C, Wakefield RJ, Emery P. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012 Aug;71(8):1316-21. doi: 10.1136/annrheumdis-2011-200548. Epub 2012 Jan 31.</citation>
    <PMID>22294638</PMID>
  </reference>
  <reference>
    <citation>Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008 Oct;58(10):2958-67. doi: 10.1002/art.23945.</citation>
    <PMID>18821687</PMID>
  </reference>
  <reference>
    <citation>Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.</citation>
    <PMID>26545940</PMID>
  </reference>
  <reference>
    <citation>Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford). 2000 Mar;39(3):321-7. doi: 10.1093/rheumatology/39.3.321.</citation>
    <PMID>10788543</PMID>
  </reference>
  <reference>
    <citation>El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. Rheumatol Int. 2012 Oct;32(10):3061-8. doi: 10.1007/s00296-011-2098-1. Epub 2011 Sep 11.</citation>
    <PMID>21909946</PMID>
  </reference>
  <reference>
    <citation>Wolfe F, Pincus T. Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999 Sep;42(9):1797-808. doi: 10.1002/1529-0131(199909)42:93.0.CO;2-Q. No abstract available.</citation>
    <PMID>10513792</PMID>
  </reference>
  <reference>
    <citation>Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000 Jul;43(7):1478-87. doi: 10.1002/1529-0131(200007)43:73.0.CO;2-M.</citation>
    <PMID>10902749</PMID>
  </reference>
  <reference>
    <citation>Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S14-36. doi: 10.1002/acr.20621. No abstract available.</citation>
    <PMID>22588741</PMID>
  </reference>
  <reference>
    <citation>Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, Solomon DH. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012 May;71(5):681-6. doi: 10.1136/ard.2011.154625. Epub 2011 Oct 12.</citation>
    <PMID>21994234</PMID>
  </reference>
  <reference>
    <citation>Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther. 2009;11(5):244. doi: 10.1186/ar2745. Epub 2009 Oct 14.</citation>
    <PMID>19849821</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Impact</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03228342
org study id: IRE-2218-17/19-1
nct id: NCT03228342
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Evaluate the impact of MusculoSkeletal Ultrasound added to Rheumatoid Arthritis patients
      classified in remission/low disease activity in terms of Patient Reported Outcomes.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Other
masking: Double (Participant, Outcomes Assessor)
measure: Change from Baseline of the Patient Reported Outcome (HAQ)
time frame: From baseline at 6 months
description: Minimal Clinically Significant change in HAQ
measure: Change from Baseline of the Patient Reported Outcome (RADAI)
time frame: from baseline at 6 months
description: Minimal Clinically Significant change in RADAI
measure: Change from Baseline of the Patient Reported Outcome (SF-36)
time frame: from baseline at 6 months
description: Minimal Clinically Significant change in SF-36
measure: Change from Baseline of the Patient Reported Outcome (VAS-Patient)
time frame: from baseline at 6 months
description: Minimal Clinically Significant change in VAS-Patient
measure: Ultrasound findings in Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity
time frame: Baseline
description: Describe ultrasound findings at the moment of inclusion in the study.
measure: Clinical relapse: Proportion of patients with relapse after the intervention in both groups
time frame: baseline and 6 months
description: Describe the proportion of patients with relapse after the intervention in both groups.
measure: Change from Baseline of the Patient Reported Outcome (HAQ)
time frame: from baseline at 12 months
description: Minimal Clinically Significant change in HAQ
measure: Change from Baseline of the Patient Reported Outcome (RADAI)
time frame: from baseline at 12 months
description: Minimal Clinically Significant change in RADAI
measure: Change from Baseline of the Patient Reported Outcome (SF-36)
time frame: from baseline at 12 months
description: Minimal Clinically Significant change in SF-36
measure: Change from Baseline of the Patient Reported Outcome (VAS-Patient)
time frame: from baseline at 12 months
description: Minimal Clinically Significant change in VAS-Patient
arm group label: Ultrasound shared
arm group type: Experimental
description: Patient will be assessed with ultrasound (GUS-7 score)
arm group label: Ultrasound not shared
arm group type: Experimental
description: Patient will be assessed with ultrasound (GUS-7 score)
intervention type: Diagnostic Test
intervention name: MusculoSkeletal Ultrasound
description: Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.
arm group label: Ultrasound shared
intervention type: Diagnostic Test
intervention name: MusculoSkeletal Ultrasound
description: Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization.
arm group label: Ultrasound not shared
criteria: 
gender: All
minimum age: 16 Years
maximum age: N/A
healthy volunteers: No
last name: Virginia Pascual, MD
role: Study Director
affiliation: INCMNSZ
facility: 
country: Mexico
citation: Plaza M, Nowakowska-Plaza A, Pracon G, Sudol-Szopinska I. Role of ultrasonography in the diagnosis of rheumatic diseases in light of ACR/EULAR guidelines. J Ultrason. 2016 Mar;16(64):55-64. doi: 10.15557/JoU.2016.0006. Epub 2016 Mar 29.
PMID: 27104003
citation: Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, Green MJ, Veale DJ, Isaacs JD, Emery P. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum. 2000 Dec;43(12):2762-70. doi: 10.1002/1529-0131(200012)43:123.0.CO;2-#.
PMID: 11145034
citation: Nakagomi D, Ikeda K, Okubo A, Iwamoto T, Sanayama Y, Takahashi K, Yamagata M, Takatori H, Suzuki K, Takabayashi K, Nakajima H. Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum. 2013 Apr;65(4):890-8. doi: 10.1002/art.37848.
PMID: 23334942
citation: Terslev L, von der Recke P, Torp-Pedersen S, Koenig MJ, Bliddal H. Diagnostic sensitivity and specificity of Doppler ultrasound in rheumatoid arthritis. J Rheumatol. 2008 Jan;35(1):49-53. Epub 2007 Dec 15.
PMID: 18172922
citation: Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli G. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011 Jan;70(1):172-5. doi: 10.1136/ard.2010.129924. Epub 2010 Nov 19.
PMID: 21097799
citation: Dale J, Purves D, McConnachie A, McInnes I, Porter D. Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken). 2014 Jan;66(1):19-26. doi: 10.1002/acr.22218.
PMID: 24376248
citation: Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12.
PMID: 25969430
citation: Galicia-Hernandez G, Parra-Salcedo F, Ugarte-Martinez P, Contreras-Yanez I, Ponce-de-Leon A, Pascual-Ramos V. Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):261-9. Epub 2016 Mar 3.
PMID: 26939612
citation: Backhaus M, Ohrndorf S, Kellner H, Strunk J, Backhaus TM, Hartung W, Sattler H, Albrecht K, Kaufmann J, Becker K, Sorensen H, Meier L, Burmester GR, Schmidt WA. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum. 2009 Sep 15;61(9):1194-201. doi: 10.1002/art.24646.
PMID: 19714611
citation: Backhaus TM, Ohrndorf S, Kellner H, Strunk J, Hartung W, Sattler H, Iking-Konert C, Burmester GR, Schmidt WA, Backhaus M. The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Ann Rheum Dis. 2013 Jul;72(7):1163-9. doi: 10.1136/annrheumdis-2012-201397. Epub 2012 Sep 6.
PMID: 22956596
citation: Scire CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009 Sep;48(9):1092-7. doi: 10.1093/rheumatology/kep171. Epub 2009 Jun 26.
PMID: 19561156
citation: Saleem B, Brown AK, Quinn M, Karim Z, Hensor EM, Conaghan P, Peterfy C, Wakefield RJ, Emery P. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012 Aug;71(8):1316-21. doi: 10.1136/annrheumdis-2011-200548. Epub 2012 Jan 31.
PMID: 22294638
citation: Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008 Oct;58(10):2958-67. doi: 10.1002/art.23945.
PMID: 18821687
citation: Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.
PMID: 26545940
citation: Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford). 2000 Mar;39(3):321-7. doi: 10.1093/rheumatology/39.3.321.
PMID: 10788543
citation: El Miedany Y, El Gaafary M, Palmer D. Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. Rheumatol Int. 2012 Oct;32(10):3061-8. doi: 10.1007/s00296-011-2098-1. Epub 2011 Sep 11.
PMID: 21909946
citation: Wolfe F, Pincus T. Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999 Sep;42(9):1797-808. doi: 10.1002/1529-0131(199909)42:93.0.CO;2-Q. No abstract available.
PMID: 10513792
citation: Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000 Jul;43(7):1478-87. doi: 10.1002/1529-0131(200007)43:73.0.CO;2-M.
PMID: 10902749
citation: Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S14-36. doi: 10.1002/acr.20621. No abstract available.
PMID: 22588741
citation: Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, Solomon DH. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012 May;71(5):681-6. doi: 10.1136/ard.2011.154625. Epub 2011 Oct 12.
PMID: 21994234
citation: Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther. 2009;11(5):244. doi: 10.1186/ar2745. Epub 2009 Oct 14.
PMID: 19849821
responsible party type: Sponsor
mesh term: Arthritis
mesh term: Arthritis, Rheumatoid